BiotechTube

Topical IBU twice daily + Placebo twice daily + Topical IBU three times daily + Placebo three times daily

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ankle Injuries

Conditions

Ankle Injuries

Trial Timeline

Nov 1, 2013 → Feb 1, 2015

NCT ID
NCT01945034

About Topical IBU twice daily + Placebo twice daily + Topical IBU three times daily + Placebo three times daily

Topical IBU twice daily + Placebo twice daily + Topical IBU three times daily + Placebo three times daily is a phase 3 stage product being developed by Pfizer for Ankle Injuries. The current trial status is completed. This product is registered under clinical trial identifier NCT01945034. Target conditions include Ankle Injuries.

What happened to similar drugs?

3 of 6 similar drugs in Ankle Injuries were approved

Approved (3) Terminated (0) Active (3)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅diclofenac potassium 25 mg tablet + placeboNovartisApproved
🔄Diclofenac SodiumNovartisPhase 3
🔄diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3
🔄Diclofenac sodium topical gel 1% + PlaceboNovartisPhase 3
✅Non-selective NSAIDS + CelecoxibPfizerApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01945034Phase 3Completed

Competing Products

7 competing products in Ankle Injuries

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
diclofenac potassium 25 mg tablet + placeboNovartisApproved
43
Diclofenac SodiumNovartisPhase 3
40
Diclofenac diethylamine 2.32% gel + Placebo + Diclofenac diethylamine 2.32% gel / PlaceboNovartisPhase 2
35
diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3
40
Diclofenac sodium topical gel 1% + PlaceboNovartisPhase 3
40
Non-selective NSAIDS + CelecoxibPfizerApproved
43